CRF2 Agonist for Heart Failure
(CRAFT-WHF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, COR-1167, a CRF2 agonist, to determine its effectiveness for patients hospitalized with worsening heart failure. The trial includes three groups receiving low, medium, and high doses of the drug, along with a placebo group. Individuals hospitalized for heart failure in the past year who require IV diuretics (medication to remove excess fluid) may qualify. The trial aims to assess whether COR-1167 can improve symptoms and outcomes for heart failure patients. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to significant medical advancements.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you must be on an oral loop diuretic for at least a month before joining the study.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that COR-1167 is generally safe and well-tolerated in earlier studies. Tests with both healthy volunteers and patients revealed promising safety results, with no major side effects reported. This suggests the treatment might be safe for most people.
Although this trial is in an early stage, COR-1167 has already passed initial safety tests. However, further studies are needed to confirm these findings in people with heart failure. As the trial progresses, researchers will closely monitor safety.12345Why do researchers think this study treatment might be promising for heart failure?
Researchers are excited about COR-1167 for heart failure because it offers a novel approach compared to existing treatments like ACE inhibitors, beta-blockers, and diuretics. Unlike these standard therapies, COR-1167 acts as a CRF2 agonist, targeting a unique pathway that could improve heart function more effectively. This new mechanism of action holds the potential for enhanced outcomes in heart failure management, sparking optimism among researchers.
What evidence suggests that this trial's treatments could be effective for heart failure?
Research has shown that COR-1167, a new treatment under study in this trial, offers promising results for people with worsening heart failure. This treatment activates a specific pathway in the body that protects the heart and improves its function. In earlier studies, patients who received COR-1167 demonstrated noticeable improvements in heart function. In this trial, participants will receive different doses of COR-1167 or a placebo. The treatment is administered once a day through an injection just under the skin. These findings suggest that COR-1167 could be an effective option for those with worsening heart failure.12346
Who Is on the Research Team?
Jeffrey Testani, MD
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
This trial is for adults hospitalized with worsening heart failure who've had a similar hospital stay in the past year. They must have certain blood markers indicating heart stress, be on specific diuretics for at least a month, and show signs of resistance to these drugs. Participants need to join within 48 hours of their current hospital admission.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the investigational drug COR-1167 or placebo for worsening heart failure
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- COR-1167
Find a Clinic Near You
Who Is Running the Clinical Trial?
Corteria Pharmaceuticals
Lead Sponsor
Worldwide Clinical Trials
Collaborator